Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof
US-2024390298-A1 · Nov 28, 2024 · US
US10980755B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10980755-B2 |
| Application number | US-201615758549-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 9, 2016 |
| Priority date | Sep 10, 2015 |
| Publication date | Apr 20, 2021 |
| Grant date | Apr 20, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are compositions and methods for modulating the liver receptor homolog-1.
Opening claim text (preview).
What is claimed is: 1. A compound having the formula: wherein W 1 and W 2 are independently CH or N; L 1 is C(O)NH—, —NHC(O)—, or —NHC(NH)NH; R 1 is unsubstituted alkyl; R 2 is unsubstituted tert-butyl; R 3 is unsubstituted tert-butyl; R 4 is —OR 22 ; R 22 is hydrogen, halogen, —CX 3 , —CHX 2 , —CH 2 X, —OCX 3 , —OCH 2 X, —OCHX 2 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC═(O)NHNH 2 , —NHC═(O) NH 2 , —NHSO 2 H, —NHC═(O)H, —NHC(O)—OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; X is —Cl, —Br, —I, or —F; wherein R 1 is not unsubstituted methyl or unsubstituted tert-butyl; and wherein the compound does not have the formula 2. The compound of claim 1 , wherein R 1 is unsubstituted C 1 -C 8 alkyl. 3. The compound of claim 1 , having the formula: 4. The compound of claim 1 , wherein R 1 is unsubstituted C 1 -C 6 alkyl. 5. The compound of claim 1 , wherein R 4 is —OH. 6. The compound of claim 1 , wherein R 1 is unsubstituted butyl, unsubstituted pentyl, or unsubstituted hexyl. 7. The compound of claim 1 , wherein R 1 is unsubstituted C 3 -C 5 alkyl. 8. The compound of claim 1 , wherein R 1 is unsubstituted n-butyl. 9. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 10. The compound of claim 1 , having the formula
Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Amides · CPC title
Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom · CPC title
the carbon skeleton being further substituted by singly-bound oxygen atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.